U.S. Computer Aided Detection (CAD) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Computer Aided Detection (CAD) Market Size

• The U.S. computer aided detection (CAD) market size was valued at USD 831.39 million in 2024 and is expected to reach USD 2,058.51 million by 2032, at a CAGR of 12.00% during the forecast period
• The market growth is largely fueled by the increasing demand for early and accurate detection of chronic diseases such as breast cancer, lung cancer, and colorectal cancer, driving the need for Computer Aided Detection (CAD) systems across hospitals and diagnostic imaging centers in the U.S. CAD technologies enhance image interpretation accuracy, reduce human error, and assist radiologists in identifying subtle abnormalities—factors that contribute to improved clinical outcomes and growing adoption of these tools
• Furthermore, advancements in AI-based imaging algorithms, integration of CAD with PACS (Picture Archiving and Communication Systems), and supportive regulatory approvals from the U.S. FDA are accelerating the adoption of Computer Aided Detection solutions in the country. These developments, combined with the rising volume of diagnostic imaging procedures and growing emphasis on preventive healthcare, are positioning the U.S. CAD market for robust growth over the forecast period

U.S. Computer Aided Detection (CAD) Market Analysis

• Computer Aided Detection (CAD) systems, enabling patients with end-stage renal disease to manage treatment from home, are becoming increasingly vital in modern healthcare due to their ability to improve patient comfort, reduce hospital visits, and lower healthcare costs. These systems offer flexibility in scheduling, improved quality of life, and are being rapidly adopted in both urban and rural settings
• The accelerating demand for Computer Aided Detection (CAD) in the U.S. is primarily fueled by the rising prevalence of chronic kidney disease (CKD), increasing awareness of home-based renal care, technological advancements in compact and user-friendly dialysis machines, and growing support from insurance providers for at-home treatments
• U.S. held a market share of 42.8% in North America in computer aided detection (CAD) market in 2024. This is attributed to the country’s advanced healthcare infrastructure, strong presence of key market players like Fresenius Medical Care and Baxter International, and supportive reimbursement policies
• The group purchase organization segment dominated the U.S. computer aided detection (CAD) market with a market share of 66.5% in 2024, due to bulk purchasing by hospitals and healthcare systems for cost savings. This procurement model allows healthcare providers to access CAD solutions at reduced prices, ensuring budget efficiency while equipping facilities with advanced diagnostic technologies. The prevalence of centralized purchasing among large healthcare networks is a key factor driving the dominance of this segment

Report Scope and U.S. Computer Aided Detection (CAD) Market Segmentation

U.S. Computer Aided Detection (CAD) Market Trends

“Advancing Home-Based Dialysis Through Intelligent Connectivity”

• A significant and accelerating trend in the U.S. computer aided detection (CAD) market is the growing integration of intelligent technologies and remote patient monitoring systems. This convergence is transforming how patients and clinicians manage home dialysis, offering enhanced convenience, safety, and improved clinical outcomes
• For instance, Baxter’s Sharesource platform enables healthcare providers to remotely monitor home dialysis treatments in real time, facilitating timely interventions and personalized adjustments, which in turn reduce hospital visits and improve adherence to therapy protocols
• Modern Computer Aided Detection (CAD) devices powered by smart technologies can interpret patient data to provide personalized therapy recommendations, detect anomalies like fluid imbalances or clotting risks, and issue real-time alerts to healthcare providers. This approach ensures more proactive and effective patient care
• Features such as smartphone-based interfaces and voice-assistant compatibility are becoming increasingly common, allowing patients to manage their dialysis sessions with greater ease. These tools enhance accessibility and independence, particularly for elderly or mobility-limited individuals
• Integration with broader smart home ecosystems is also on the rise, enabling treatment reminders, alerts, and updates to be synced with wearables, virtual assistants, and IoT-enabled platforms. This holistic approach supports a more connected and supportive healthcare environment within the home
• This trend toward intuitive, connected, and patient-focused dialysis systems is reshaping expectations and driving innovation across the sector. Key players such as Fresenius Medical Care and Outset Medical are at the forefront of this shift, developing advanced solutions that combine automation, clinical accuracy, and user-friendly operation
• As the U.S. healthcare system continues to transition toward decentralized, personalized, and tech-enabled care delivery models, the demand for CAD solutions with integrated smart capabilities is expected to grow significantly, especially in the context of home-based chronic disease management

U.S. Computer Aided Detection (CAD) Market Dynamics

Driver

“Rising Integration of AI and Imaging Analytics in U.S. Clinical Practice”

• The growing use of artificial intelligence and advanced imaging technologies in clinical workflows is fueling the adoption of Computer Aided Detection (CAD) systems in the U.S. These tools are increasingly used to enhance early disease detection, reduce diagnostic errors, and improve radiologist efficiency
• In breast cancer screening, for example, CAD tools help identify microcalcifications and subtle anomalies that may be missed in manual reviews, significantly improving detection rates
• Leading hospitals and diagnostic centers in the U.S. are integrating AI-enhanced CAD into mammography, chest CTs, and MRI for neurological conditions—accelerating diagnosis and enabling more targeted treatment planning
• The U.S. FDA has also accelerated approvals for CAD technologies under its breakthrough device designation, encouraging innovation and adoption
•  The increasing shortage of radiologists in the U.S. is driving healthcare systems to invest in CAD tools as a clinical support system, ensuring timely image analysis and reducing radiologist burnout
•  Insurance providers and payers are showing growing willingness to reimburse AI-based diagnostic support tools, boosting the commercial viability of CAD systems in routine diagnostics
• Academic institutions and research hospitals are collaborating with technology firms to conduct large-scale studies on CAD utility, accelerating real-world validation and deployment across healthcare settings

Restraint/Challenge

“Interoperability Issues and Limited AI Transparency Hinder Full Integration”

• Despite advancements, many healthcare providers struggle with integrating CAD tools into legacy radiology systems, PACS, or EHRs, creating workflow bottlenecks and data silos
• Another concern is the lack of transparency or explainability in AI-driven CAD decisions, which raises trust issues among radiologists and clinicians. Many professionals hesitate to rely fully on automated outputs without understanding the rationale behind the predictions
• Smaller healthcare facilities also face budgetary constraints in adopting these technologies, given the high upfront investment and training requirements
• To overcome these barriers, vendors must focus on developing plug-and-play solutions, improve AI model explainability, and offer flexible, subscription-based pricing models to expand reach in the U.S. market
• The lack of standardized performance benchmarks across different CAD vendors makes clinical comparison and procurement decisions difficult for providers
• Some CAD tools still generate high false-positive rates, especially in dense breast tissue or complex imaging cases, leading to unnecessary follow-ups and increased patient anxiety
• Resistance to workflow change from experienced radiologists and healthcare staff—who may view AI as redundant or unreliable—further restricts CAD tool adoption in traditional healthcare setups

U.S. Computer Aided Detection (CAD) Market Scope

The market is segmented on the basis of product type, imaging modality, application, mode of purchase, and end user.

• By Product Type

On the basis of product type, the U.S. computer aided detection (CAD) market is segmented into software and services. The software segment dominated the market with the largest revenue share of 63.4% in 2024, owing to its broad application in image analysis, workflow automation, and real-time anomaly detection.

The services segment is expected to register the fastest CAGR of 8.5% from 2025 to 2032, driven by increased demand for system support, integration, training, and maintenance.

• By Imaging Modality

On the basis of imaging modality, the U.S. computer aided detection (CAD) market is segmented into breast imaging, lung imaging, oncology and radiation, abdominal and pelvic imaging, dental imaging, cardiovascular imaging, and others. The breast imaging segment held the largest revenue share of 34.7% in 2024, supported by high screening rates and government-led mammography initiatives.

The lung imaging segment is projected to grow at the fastest CAGR of 9.1% from 2025 to 2032, due to rising awareness of lung cancer and advancements in low-dose CT scan interpretation.

• By Application

On the basis of application, the U.S. computer aided detection (CAD) market is segmented into cancer, neurological disorders, cardiovascular diseases, musculoskeletal diseases, and others. The cancer segment dominated the market with the largest share of 58.2% in 2024, driven by the high incidence of breast, lung, and colorectal cancers and the need for early detection.

The neurological disorders segment is expected to grow at the fastest CAGR of 9.4% from 2025 to 2032, owing to increasing neuroimaging utilization in Alzheimer’s and Parkinson’s detection.

• By Mode of Purchase

On the basis of mode of purchase, the U.S. computer aided detection (CAD) market is segmented into group purchase organization and individual. The group purchase organization segment accounted for the largest share of 66.5% in 2024, due to bulk purchasing by hospitals and healthcare systems for cost savings.

The individual purchase segment is projected to grow at a faster CAGR of 8.7% from 2025 to 2032, driven by the rise in standalone diagnostic facilities and independent clinics adopting CAD tools.

• By End User

On the basis of end user, the U.S. computer aided detection (CAD) market is segmented into hospitals, diagnostic centers, research centers and academic institutes, and others. The hospitals segment led the market with a dominant revenue share of 49.8% in 2024, due to high patient volume, robust imaging infrastructure, and integrated health IT systems.

The diagnostic centers segment is expected to grow at the fastest CAGR of 9.2%, fueled by outpatient diagnostics and rapid CAD adoption in decentralized settings.

U.S. Computer Aided Detection (CAD) Market Regional Analysis

• The U.S. computer aided detection (CAD) market captured the largest revenue share of 42.8% in the North American market in 2024, supported by strong government initiatives such as the ESRD Treatment Choices (ETC) Model, robust digital infrastructure, and high R&D investments
• Innovative platforms such as Outset Medical’s Tablo System and widespread telehealth integration are improving accessibility and clinical outcomes
• In addition, post-pandemic shifts toward remote diagnostics and home-based care are driving rapid market expansion across varied healthcare settings

U.S. Computer Aided Detection (CAD) Market Share

The U.S. Computer Aided Detection (CAD) Market industry is primarily led by well-established companies, including:

• Koninklijke Philips N.V. (Netherlands)
• FUJIFILM Holdings Corporation (Japan)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Siemens Healthineers AG (Germany)
• Median Technologies (France)
• General Electric Company (U.S.)
• Hologic, Inc. (U.S.)
• iCAD, Inc. (U.S.)
• EDDA Technology, Inc. (U.S.)
• Riverain Technologies (U.S.)

Latest Developments in U.S. Computer Aided Detection (CAD) Market

• In June 2025, Fresenius Medical Care secured FDA 510(k) clearance for its updated 5008X CAREsystem, which supports high-volume hemodiafiltration (HVHDF) in the U.S. The system is scheduled for phased deployment across Fresenius Kidney Care clinics throughout 2025, with a full commercial launch planned for 2026
• In March 2025, the FDA reported ongoing shortages of hemodialysis bloodlines, projecting supply constraints to extend through early fall 2025. The agency advised clinicians to implement conservation strategies to maintain continuity of dialysis treatments amid the shortage
• In November 2024, Quanta Dialysis Technologies received FDA 510(k) clearance for its Quanta Dialysis System, making it the only high dialysate-flow (500 mL/min) home-use dialysis machine available in the U.S. This breakthrough enables patients to access hospital-grade performance within the home setting

SKU-70463